Unity Biotechnology Faces Nasdaq Delisting and Leadership Changes

An announcement from Unity Biotechnology ( (UBX) ) is now available.

On June 27, 2025, UNITY Biotechnology was notified by Nasdaq that its securities would be delisted due to the company’s status as a ‘public shell’ with no operating business, following a significant reduction in force and strategic evaluation. The company also announced the resignation of its board and officers, the appointment of Craig R. Jalbert as the sole director and officer, and plans for dissolution, seeking stockholder approval to proceed with winding down operations and monetizing assets.

The most recent analyst rating on (UBX) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Unity Biotechnology stock, see the UBX Stock Forecast page.

Spark’s Take on UBX Stock

According to Spark, TipRanks’ AI Analyst, UBX is a Underperform.

Unity Biotechnology’s overall score is weighed down by significant financial challenges, including persistent losses and negative equity. Technical analysis suggests a bearish trend with limited momentum. Valuation metrics reflect the unprofitability of the company. However, the recent strategic appointment to the Board provides a potential strategic advantage in its program development.

To see Spark’s full report on UBX stock, click here.

More about Unity Biotechnology

UNITY Biotechnology, Inc. operates in the biotechnology industry, focusing on developing therapeutics to slow, halt, or reverse diseases of aging. However, the company has faced challenges with limited operations, lack of revenue, and minimal investment in revenue-producing assets.

Average Trading Volume: 276,394

Technical Sentiment Signal: Sell

Current Market Cap: $13.28M

Learn more about UBX stock on TipRanks’ Stock Analysis page.